Search Results

90 results

  1. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 12

    Review of current methodologies in evaluating abuse liability of nicotine and tobacco products in the U.S. regulatory environment

    EVANS S.(1); KONG M.C.(2); CAMPBELL L.(2); SHERWOOD N.(3); PRASAD K.(4)
    (1) Turning Point Brands, Louisville, KY, U.S.A.; (2) Altasciences Clinical Research, Laval, Canada; (3) Neil Sherwood Consulting, Nyon, Switzerland; (4) British American Tobacco, R&D, Millbrook, Southampton, U.K.
    Traditional definitions of abuse and misuse do not apply to a consumer product such as tobacco that consumers essentially use ‘as intended’. In contrast to pharmaceutical products, a guidance for abuse liability testing of nicotine and tobacco...
  2. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 52 (also presented at TSRC 2019)

    Application of differential ion mobility spectrometry-tandem mass spectrometry for improved assay selectivity and sensitivity in the quantitation of tobacco biomarkers NNN, NNAL and 2-/3-HPMA in human urine

    PLOMLEY J.B.
    Altasciences, Laval, QC, Canada
    Differential ion mobility spectrometry (DMS) has recently emerged as an orthogonal gas-phase ion separation technique which, when interfaced between liquid chromatography (LC) and tandem mass spectrometry (MS/MS), promises improvements in both assay...
  3. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 53

    NNN – a suitable biomarker of exposure from smoke and new nicotine delivery products?

    PLUYM N.; TAUCHER J.; SCHERER G.; SCHERER M.
    ABF Analytisch-Biologisches Forschungslabor GmbH, Planegg, Germany
    N-Nitrosonornicotine (NNN) is believed to play a critical role in the development of cancer in tobacco users and was therefore classified by the International Agency for Research on Cancer (IARC) as a Group 1 carcinogen. Hence, urinary NNN is...
  4. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, ST 54

    Clinical biomarkers of compliance for use in potentially reduced-risk product switching studies

    McEWAN M.(1); GALE N.(1); HARDIE G.(1); SCHERER M.(2); PLUYM N.(2); EBAJEMITO J.K.(1); CAMACHO O.M.(1); GRIFFITHS A.(1); PROCTOR C.J.(1)
    (1) British American Tobacco (Investments) Limited, Research and Development, Southampton, U.K.; (2) ABF GmbH, Planegg, Germany
    Preclinical assessments and clinical studies have shown significant reductions in toxicants in tobacco heating product (THP) aerosols compared to smoke from conventional cigarettes. Further studies to assess if these toxicant reductions translate to...
  5. CORESTA Meeting, Smoke Science/Product Technology, 2019, Hamburg, STPOST 13

    Analysis of propylene oxide and glycidol in tobacco smoke and e-cigarette vapour

    LANDMESSER A.; SCHERER G.; PLUYM N.; SCHERER M.
    ABF Analytisch-Biologisches Forschungslabor GmbH, Planegg, Germany
    We recently performed a clinical study with e-cigarette users (vapers) and smokers. The stable-isotope labeled e-cigarette constituents propylene glycol, glycerol, and nicotine in the test e-cigarette were used in order to investigate the e-cigarette...
  6. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 044

    Abuse liability of very low nicotine content cigarettes with characterization of nicotine exposure profiles in adult smokers

    LEVY-COOPERMAN N.(1); SHRAM M.J.(1); KELSH D.(2); VINCE B.(2); CARMINES E.(3)
    (1) Altreos Research Partners, Toronto, ON, Canada; (2) Altasciences/Vince and Associates, Overland Park, KS, USA; (3) Carmines Consulting, Scottsdale, AZ, USA
    Objectives: In 2017, FDA announced the intention to explore limiting nicotine in cigarettes to minimal/non-addictive levels. Research indicates that reduced nicotine content would potentially limit reinforcing effects of cigarettes. We conducted 2...
  7. TSRC, Tob. Sci. Res. Conf., 2019, 73, abstr. 102 (also presented at CORESTA SSPT2019)

    Novel application of differential ion mobility spectrometry-tandem mass spectrometry for improved assay selectivity and sensitivity in the quantitative determination of total NNN total NNAL and 2- / 3-HPMA in human urine

    PLOMLEY J.
    Altasciences, Laval, Canada
    Differential Ion Mobility Spectrometry (DMS) has recently emerged as an orthogonal gas-phase ion separation technique which, when interfaced between liquid chromatography (LC) and Tandem Mass Spectrometry (MS/MS), promises improvements in both assay...
  8. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups (Workshop), STW 07

    Identifying suitable biomarkers of biological effects (BOBEs) for evaluating reduced risk products

    SCHERER G.; PLUYM N.; SCHERER M.
    ABF Analytisch-Biologisches Forschungslabor GmbH, Planegg, Germany
    Switching from conventional cigarettes (CCs) to reduced risk products (RRPs), such as e cigarettes, heat-not-burn and oral tobacco products, could be an effective approach for tobacco harm reduction (THR), provided that the use of RRPs effectively...
  9. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 59

    An inter-laboratory comparison study focused on the determination of total NNAL in human urine

    NEWLAND K.(1); SCHERER M.(2); HECHT S.S.(3); TROUDE V.(4); PRASAD G.L.(5)
    (1) Celerion Inc., Lincoln, NE, U.S.A.; (2) ABF GmbH, Planegg, Germany; (3) University of Minnesota Cancer Center, Minneapolis, MN, U.S.A.; (4) Reemtsma Cigarettenfabriken GmbH, Imperial Brands plc, Hamburg, Germany; (5) RAI Services Company, Winston-Salem, NC, U.S.A.
    In an ongoing effort to fulfil the second objective of the CORESTA Biomarker Sub-Group, periodic inter-laboratory comparison studies have been performed to evaluate the consistency of the quantitation for various harmful or potentially harmful...
  10. CORESTA Congress, Kunming, 2018, Smoke Science/Product Technology Groups, ST 61

    Novel biomarkers to characterize exposure to aldehydes from e-vapor products based on stable-isotope constituents

    LANDMESSER A.(1); SCHERER M.(1); SCHERER G.(1); SARKAR M.(2); EDMISTON J.S.(2); PLUYM N.(1)
    (1) ABF Analytisch-Biologisches Forschungslabor GmbH, Planegg, Germany; (2) Altria Client Services LLC, Center for Research and Technology, Richmond, VA, U.S.A.
    E vapor products (EVP) are an emerging category of non-combustible tobacco products that hold the promise of harm reduction for users of combustible products. Degradation products such as aldehydes have received much attention lately, however human...